Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA
23 Jan 2024
IPOAcquisition
Plus, news about Outlook Therapeutics and Adicet Bio:
Merck and Unnatural Products collaborate:
Per the
deal
, Merck will make an undisclosed upfront payment to the Santa Cruz, CA-based biotech and up to $220 million in milestones. The companies plan to develop macrocyclic therapies for cancer.
— Jaimy Lee
CG Oncology upsizes IPO:
The Phase III bladder cancer biotech increased its offering size from
11.8 million
shares to 17 million shares
$CGON
, per a SEC
filing
on Tuesday. At the mid-point of its price range of $17.00, CG would raise about $262.8 million in its Nasdaq debut later this month. It set out a $181 million
target last week
.
— Kyle LaHucik
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.